Marksans Pharma Limited (MARKSANS) Financial History

Name: Marksans Pharma Limited (MARKSANS) financial statement history
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Drug Manufacturers - General · DATA UPDATED 2026-09-20

Marksans Pharma Limited (MARKSANS) operates in the Drug Manufacturers - General industry and is headquartered in Mumbai, India with about 1,685 employees. Its market capitalization is roughly ₹145 billion. In the fiscal year ended 2026-03-31, MARKSANS reported ₹29.4B in revenue and ₹4.2B in net income.

Marksans Pharma Limited, together with its subsidiaries, engages in the research, manufacturing, marketing, and sale of pharmaceutical formulations in the United States, North America, Europe, the United Kingdom, Australia, New Zealand, and internationally.

Interactive charts & full statements →

MARKSANS Revenue & Earnings History — Annual Income Statement

Income statement	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Revenue	₹29.4B	₹26.1B	₹21.7B	₹18.5B	—
Gross Profit	₹15.7B	₹13.8B	₹10.8B	₹8.9B	—
Operating Income (EBIT)	₹5.2B	₹4.6B	₹3.9B	₹3.1B	—
Net Income	₹4.2B	₹3.8B	₹3.1B	₹2.7B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MARKSANS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30
Total Revenue	₹8.4B	₹8.6B	₹7.5B	₹7.2B	₹6.2B
Gross Profit	₹5.0B	₹4.7B	₹4.4B	₹4.1B	₹3.6B
Operating Income (EBIT)	₹1.9B	₹1.7B	₹1.4B	₹1.2B	₹770M
Net Income	₹1.6B	₹1.5B	₹1.1B	₹982M	₹583M

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MARKSANS Free Cash Flow History

Cash flow	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Dividends Paid	(₹362M)	(₹272M)	(₹227M)	(₹102M)	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MARKSANS Balance Sheet History

Balance sheet	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Total Assets	₹38.6B	₹32.4B	₹26.8B	₹21.9B	—
Total Liabilities	₹8.1B	₹7.5B	₹6.0B	₹4.3B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MARKSANS viewer.

Other Companies in Drug Manufacturers - General

GLAXO · GlaxoSmithKline Pharmaceuticals Limited — ₹481 billion
RUBICON · Rubicon Research Limited — ₹289 billion
NOVN · Novartis AG — CHF 219 billion
PFIZER · Pfizer Limited — ₹183 billion
1093 · CSPC Pharmaceutical Group Limited — HK$102 billion
SANOFICONR · Sanofi Consumer Healthcare India Limited — ₹93 billion
SANOFI · Sanofi India Limited — ₹71 billion
SYMBIOTEC · SYMBIOTEC PHARMALAB LTD — ₹70 billion

← MARKOLINES All “M” companies MARM →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.